GlassScriptPhysician profile
Adel Yaacoub
NPI 1477572550
$4,107.63
in general payments reported to CMS, 2019-2025
31 companies · $74.04 in 2025
The $74.04 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,003 · 2020: $528 · 2021: $204 · 2022: $284 · 2023: $1,015 · 2025: $74.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Research Incorporated | $1,102.50 | 2019-2020 | |
| Abiomed | $473.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $408.74 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $375.95 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $252.76 | 2019-2023 | |
| Amgen INC. | $236.31 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $221.81 | 2019-2023 | |
| Pfizer INC. | $163.06 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.71 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $101.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $94.91 | 2019-2023 | Farxiga |
| Abbott Laboratories | $84.76 | 2019-2023 | Confirm Rx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.16 | 2019-2023 | Lifevest |
| Cardiovascular Systems INC. | $54.80 | 2020-2023 | Diamondback Coronary |
| Actelion Pharmaceuticals US, INC. | $40.09 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $37.88 | 2019-2023 | Ozempic |
| Merck Sharp & Dohme LLC | $31.32 | 2023 | Verquvo |
| Astellas Pharma US INC | $29.39 | 2019 | |
| Penumbra, INC. | $23.51 | 2022 | |
| Medtronic Vascular, INC. | $21.25 | 2020 | |
| Teleflex LLC | $18.41 | 2022 | |
| Philips North America LLC | $16.96 | 2021 | |
| Edwards Lifesciences Corporation | $16.16 | 2019 | |
| Medtronic, INC. | $16.11 | 2023 | Linq II |
| Lexicon Pharmaceuticals, INC. | $15.70 | 2023 | Inpefa |
| Amarin Pharma, INC. | $15.33 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.94 | 2019 | |
| Scpharmaceuticals INC. | $13.07 | 2023 | |
| Acadia Pharmaceuticals INC | $12.85 | 2019 | |
| Chiesi USA, INC. | $12.71 | 2023 | Cleviprex, Kengreal |
| Biotronik INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Yaacoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.